RT Book, Section
A1 Giuliano, Vanessa
A1 Chan, Sze Wah Samuel
SR Print(0)
ID 1208767089
T1 Subcutaneous amivantamab with lazertinib is non-inferior to intravenous administration, with fewer adverse reactions
T2 2 Minute Medicine
YR 2015
FD 2015
PB McGraw Hill
PP New York, NY
SN 
LK accessmedicine.mhmedical.com/updatesContent.aspx?gbosid=649041
RD 2024/10/15
AB